World's Best Scientists 2026 revealed!
Ursula A. Matulonis

Ursula A. Matulonis

D-Index & Metrics

Medicine

D-Index
112
Citations
52802
World Ranking
5105
National Ranking
2760

Ursula A. Matulonis publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ursula A. Matulonis sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,004 publications — 94th percentile

94% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Ursula A. Matulonis D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ursula A. Matulonis sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 112 D-Index — 75th percentile

75% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Ursula A. Matulonis is affiliated with Harvard University in the United States. Their research primarily focuses on medicine, with a substantial contribution to biochemistry, genetics, and molecular biology. Within these broad fields, their work concentrates notably on oncology, reproductive medicine, and molecular biology, with additional involvement in pulmonary and respiratory medicine as well as obstetrics and gynecology.

The main topics addressed in their research include ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, endometrial and cervical cancer treatments, advanced breast cancer therapies, cancer genomics and diagnostics, cancer immunotherapy and biomarkers, and cancer mechanisms and therapy.

They have published extensively in various scientific journals, with frequent contributions to:

  • Gynecologic Oncology
  • Journal of Clinical Oncology
  • Cancer Research
  • Gynecologic Oncology Reports
  • Clinical Cancer Research

Ursula A. Matulonis has collaborated with several frequent coauthors, including:

  • Panagiotis A. Konstantinopoulos
  • Joyce F. Liu
  • Susana M. Campos
  • Alexi A. Wright
  • Neil S. Horowitz

Their recent papers include:

  • A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors, 2020, Nature Medicine
  • A single-cell landscape of high-grade serous ovarian cancer, 2020, Nature Medicine
  • Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer, 2020, Nature Communications
  • Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study, 2023, Journal of Clinical Oncology
  • Clinical and translational advances in ovarian cancer therapy, 2023, Nature Cancer

Best Publications

  • Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

    Mansoor R. Mirza;Bradley J. Monk;Jørn Herrstedt;Amit M. Oza

  • Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

    Andrew Tutt;Mark Robson;Judy E Garber;Susan M Domchek

  • Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

    Jonathan Ledermann;Philipp Harter;Charlie Gourley;Michael Friedlander

  • Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

    Jonathan Ledermann;Philipp Harter;Charlie Gourley;Michael Friedlander

  • Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer

    Stephen A. Cannistra;Ursula A. Matulonis;Richard T. Penson;Julie Hambleton

  • Place of Death: Correlations With Quality of Life of Patients With Cancer and Predictors of Bereaved Caregivers' Mental Health

    Alexi A. Wright;Nancy L. Keating;Tracy A. Balboni;Ursula A. Matulonis

  • A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors

    Michal Slyper;Caroline B. M. Porter;Orr Ashenberg;Julia Waldman

  • Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.

    Kyle C. Strickland;Brooke E Howitt;Sachet A Shukla;Scott J. Rodig

  • Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases

    Mariana C. Castells;Nichole M. Tennant;David E. Sloane;F. Ida Hsu

  • Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1

    Brooke Elizabeth Howitt;Sachet Shukla;Lynette Marie Sholl;Lauren Lee Ritterhouse

  • Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

    Triona Ni Chonghaile;Kristopher A. Sarosiek;Thanh Trang Vo;Jeremy A. Ryan

  • Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

    Joyce F. Liu;William T. Barry;Michael Birrer;Jung Min Lee

  • Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

    Stan B. Kaye;Jan Lubinski;Ursula Matulonis;Joo Ern Ang

  • Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

    U.A. Matulonis;R. Shapira-Frommer;A.D. Santin;A.S. Lisyanskaya

  • Clinical Activity of Trastuzumab and Vinorelbine in Women With HER2-Overexpressing Metastatic Breast Cancer

    Harold J. Burstein;Irene Kuter;Susana M. Campos;Rebecca S. Gelman

  • Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

    Jonathan A Ledermann;Philipp Harter;Charlie Gourley;Michael Friedlander

  • Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

    Kathleen N Moore;Angeles Alvarez Secord;Melissa A Geller;David Scott Miller

  • PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.

    Liya Ding;Hye-Jung Kim;Qiwei Wang;Michael Kearns

  • Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

    Panagiotis A. Konstantinopoulos;Steven Waggoner;Gregory A. Vidal;Monica Mita

  • Institutional implementation of clinical tumor profiling on an unselected cancer population

    Lynette M. Sholl;Khanh Do;Priyanka Shivdasani;Ethan Cerami

Frequent Co-Authors

Michael J. Birrer
Michael J. Birrer University of Arkansas for Medical Sciences
Ross S. Berkowitz
Ross S. Berkowitz Harvard Medical School
Kathleen N. Moore
Kathleen N. Moore University of Oklahoma Health Sciences Center
Hang Lee
Hang Lee Harvard University
Ronny Drapkin
Ronny Drapkin University of Pennsylvania
David M. O'Malley
David M. O'Malley The Ohio State University
Jonathan A. Ledermann
Jonathan A. Ledermann University College London
Gini F. Fleming
Gini F. Fleming University of Chicago
Alan D. D'Andrea
Alan D. D'Andrea Dana-Farber Cancer Institute
Geoffrey I. Shapiro
Geoffrey I. Shapiro Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in studying Medicine in the USA, there are many alternative degrees and career paths in the healthcare field to consider. For those looking for accessible options, there are easy nursing schools to get into that offer supportive admission processes and can be a great starting point for a healthcare career.

For students who prefer remote study or need flexible schedules, you might explore online medical billing and coding schools that accept fafsa. These programs open doors to in-demand roles in healthcare administration and records management, while also allowing you to apply for federal financial aid.

Some programs lower barriers further, like those nursing school that does not require teas test, removing common entrance exam hurdles for applicants and streamlining the pathway to a nursing degree.

Additionally, for career-driven students, there are healthcare administration degree programs that can be completed online in an accelerated format, providing leadership training for administrative roles within the healthcare sector.

Best Scientists Citing Ursula A. Matulonis

Trending Scientists

Recently Published Articles